Happiness Capital
VC Fund
Hong Kong, Hong Kong
Happiness Capital is a venture capital firm that invests in startups that aim to improve the world’s happiness. The firm helps entrepreneurs to co-create a happier world as a global community. Its investment portfolio covers seed to growth-stage companies in the US, Europe, Israel, China, and Hong Kong, with the focus on the future of food, health,education, and work.Happiness Capital was founded in 2017 and is headquartered in Hong Kong.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Happiness Capital invests in
Stages Happiness Capital invests in
Countries Happiness Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $2M–$9.3M
- Series A
- $10M–$45M
- Series B
- $8.7M–$61M
Investment Focus
Industry
- Biotechnology 13 (33%)
- Food and Beverage 7 (18%)
- Life Science 4 (10%)
- AgTech 3 (8%)
- Health Care 3 (8%)
Stage
- Series A 12 (31%)
- Seed 10 (26%)
- Series B 5 (13%)
- Venture - Series Unknown 3 (8%)
- Series C 2 (5%)
Country
- Germany 8 (21%)
- United States 8 (21%)
- United Kingdom 4 (10%)
- Israel 2 (5%)
- China 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Allan Chan
Executive Director
|
Executive Director | Total investments: 0 | Find email | |
Eric Ng
Managing Director & CEO
|
Managing Director & CEO | Total investments: 8 | Find email | |
Mark Chan
VP, Investment
|
VP, Investment | Total investments: 0 | Find email | |
Sammy Lee
Chief Invisible Officer
|
Chief Invisible Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Epoch Biodesign
|
Mellizyme Biotechnology is currently operating in stealth. | $12M / Venture - Series Unknown / Mar 25, 2026 | |
Innovacell
|
Innovacell is a biotechnology firm entirely focused on the area of tissue engineering and it operates one of Europe's largest and most modern production facilities for the proliferation of the body's own tissue cells. Its supervisory board is chaired by the experienced financial expert, Dr. Harald Pöttinger, a director of Alpine EquityManagement AG, based in Bregenz, Austria. Innovacell currently employs 20 staff as well as numerous outside experts. | Series D / Aug 21, 2025 | |
|
Epoch Biodesign
|
Mellizyme Biotechnology is currently operating in stealth. | $18.3M / Series A / Mar 05, 2025 | |
Project Eaden
|
Project Eaden combines pioneering technology with an immense love for life and food. | $15.6M / Series A / Jan 22, 2025 | |
Formo
|
Formo is Europe’s first cellular agriculture company developing animal-free dairy products using real, nature-identical milk proteins derived from precision fermentation. | $61M / Series B / Sep 09, 2024 | |
NovoNutrients
|
NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems. | $18M / Series A / Jul 09, 2024 | |
Xias Bio
|
Xias Bio is a biotechnology startup specializing in the production of recombinant proteins, offering formulators advanced soluble, active ingredients with improved attributes such as enhanced gel and film formation, as well as antioxidant properties. The company creates non-immunogenic natural motifs to produce a better delivery platform offunctionalities for research, beauty, and healthcare. | $4.8M / Seed / May 01, 2024 | |
Infinite Roots
|
Infinite Roots is a technology-driven company that harnesses natural ingredients to create sustainable health and wellness products. They emphasize using organic and ethically sourced materials, blending traditional remedies with modern science to promote holistic well-being. Infinite Roots offers a range of products, including herbal supplements,skincare, and wellness solutions, all aimed at supporting natural healing and balance. They aim to create eco-friendly, effective products while maintaining a deep commitment to environmental sustainability and ethical practices. | $57.5M / Series B / Jan 25, 2024 | |
CellRev
|
high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro. | $1.3M / Seed / Dec 04, 2023 | |
|
TômTex Co
|
100% naturally bio-based material made from food waste | $2.4M / Seed / Nov 16, 2023 | |
| See all 39 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Happiness Capital invest in?
Happiness Capital invests primarily in Biotechnology, Food and Beverage and Life Science startups, most often at Series A and Seed stage. Most of the 39 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Happiness Capital's check size?
Happiness Capital typically joins rounds of $2M–$9.3M at Seed, $10M–$45M at Series A and $8.7M–$61M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Happiness Capital participates in.
How do I contact Happiness Capital?
Public channels for Happiness Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Happiness Capital?
The team at Happiness Capital includes Allan Chan (Executive Director), Eric Ng (Managing Director & CEO) and Mark Chan (VP, Investment). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
